Multi-kinase-IN-8

Multi-kinase-IN-8 (Compound 5j) inhibits the proliferation of cancer cell lines, with IC₅₀ of 1.30 μM (MB 231 cell), 9.53 μM (MCF-7 cell), 2.07 μM (A549 cell), and 2.28 μM (Caco-2 cell), respectively^[1].
Multi-kinase-IN-8 (2.07 μM, 72 h) inhibits VEGFR-2 in Caco-2 cells^[1].
Multi-kinase-IN-8 (24 h and 48 h) induces cell cycle arrest at the G1 phase in Caco-2 cells^[1].
Multi-kinase-IN-8 (24 h and 48 h) induces cell death by triggering apoptosis in Caco-2 cells^[1].
Multi-kinase-IN-8 (24 h and 48 h) downregulates HIF-1α mRNA expression, and reduces PGE2, total VEGFR-2, p-VEGFR-2 production in MDA-MB 231^[1].
Multi-kinase-IN-8 has selective targeting potential towards the tumor-associated CA isoforms, particularly hCA IX, due to its interaction with the catalytic zinc binding site^[1].
Multi-kinase-IN-8 reduces expression levels of the initiator caspase-9 and mitochondrial apoptotic markers Bcl-2 and Bax in Caco-2 cells^[1].

MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.